Local Lidocaine Infiltration for Pain Management Post Cesarean Delivery.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00737542|
Recruitment Status : Unknown
Verified August 2008 by Soroka University Medical Center.
Recruitment status was: Not yet recruiting
First Posted : August 19, 2008
Last Update Posted : November 26, 2009
|Condition or disease||Intervention/treatment||Phase|
|Pain Cesarean Delivery||Drug: lidocaine Drug: NACL 0.9%||Not Applicable|
The studied population would be based on women who are scheduled for an elective cesarean delivery under general/spinal analgesia using a transverse lower abdominal incision.
Prior to each operation, the surgeon will be provided with a syringe containing a 20 mL solution of 1% lidocaine or 0.9% sodium chloride, which will be injected subcutaneously to the incisional site region after anesthesia and before the beginning of the surgery.
After the operation the conventional post cesarean analgesic regime will be used and recorded for all women.
The self-report of pain will be assessed by the patient using a validated visual analog scale, as instructed by the nursing staff.
The patient's mark will be used as a numerical index of pain intensity. The reports will be taken by the patients in intervals of 4 hours for 48 hours after the operation. In addition, analgesic requirements of the patient will be monitored and recorded by the nursing staff and used for comparison between the two study group
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Prospective Randomized Double-blind, Placebo-controlled Study of the Effect of Preoperative Analgesia With Local Lidocaine Infiltration for Pain Management Post Cesarean Delivery.|
|Placebo Comparator: A||
Drug: NACL 0.9%
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00737542
|Division of Obstetrics and Gynecology - Soroka University Medical Center|
|Beer-Sheva, Israel, Box 151|
|Contact: Roy S Kessous, MD 972-4722013 email@example.com|
|Principal Investigator: Roy Kessous, MD|